New cancer drug HBM1020 tested in tiny early trial
NCT ID NCT05824663
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, it is too small and early to know if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HBM1020 (a monoclonal antibody given intravenously)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 17 participants, focused on safety. It is not designed to prove effectiveness, and many early-stage drugs do not advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Denver Health
Denver, Colorado, 80204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a new drug shrink Hard-to-Treat tumors?